ENTRADA THERAPEUTICS INC (TRDA) Stock Price, Quote, News and Overview
NASDAQ:TRDA - Nasdaq - US29384C1080 - Common Stock - Currency: USD
TRDA Quote, Performance and Key Statistics
9.09
-0.14 (-1.52%)
The current stock price of TRDA is 9.09 USD. In the past month the price increased by 14.48%. In the past year, price decreased by -36.61%.
TRDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.09 | 346.84B | ||
| AMGN | AMGEN INC | 13.49 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1724.79 | 128.59B | ||
| GILD | GILEAD SCIENCES INC | 13.28 | 128.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.62 | 65.17B | ||
| ARGX | ARGENX SE - ADR | 345.61 | 40.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.40B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 21.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.81B | ||
| BIIB | BIOGEN INC | 7.7 | 17.85B |
Related stock screener links
About TRDA
Company Profile
Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 183 full-time employees. The company went IPO on 2021-10-29. The company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The firm is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The company is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. The company has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Company Info
ENTRADA THERAPEUTICS INC
One Design Center Place, Suite 17-500
Boston MASSACHUSETTS US
CEO: Dipal Doshi
Employees: 168
Phone: 18573051825
ENTRADA THERAPEUTICS INC / TRDA FAQ
What is the stock price of ENTRADA THERAPEUTICS INC today?
The current stock price of TRDA is 9.09 USD. The price decreased by -1.52% in the last trading session.
What is the ticker symbol for ENTRADA THERAPEUTICS INC stock?
The exchange symbol of ENTRADA THERAPEUTICS INC is TRDA and it is listed on the Nasdaq exchange.
On which exchange is TRDA stock listed?
TRDA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ENTRADA THERAPEUTICS INC stock?
11 analysts have analysed TRDA and the average price target is 24.82 USD. This implies a price increase of 173.05% is expected in the next year compared to the current price of 9.09. Check the ENTRADA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ENTRADA THERAPEUTICS INC worth?
ENTRADA THERAPEUTICS INC (TRDA) has a market capitalization of 344.97M USD. This makes TRDA a Small Cap stock.
How many employees does ENTRADA THERAPEUTICS INC have?
ENTRADA THERAPEUTICS INC (TRDA) currently has 168 employees.
What are the support and resistance levels for ENTRADA THERAPEUTICS INC (TRDA) stock?
ENTRADA THERAPEUTICS INC (TRDA) has a support level at 7.89 and a resistance level at 9.24. Check the full technical report for a detailed analysis of TRDA support and resistance levels.
Is ENTRADA THERAPEUTICS INC (TRDA) expected to grow?
The Revenue of ENTRADA THERAPEUTICS INC (TRDA) is expected to decline by -80.33% in the next year. Check the estimates tab for more information on the TRDA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ENTRADA THERAPEUTICS INC (TRDA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TRDA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TRDA, evaluating the profitability, health, valuation and growth aspects
- ENTRADA THERAPEUTICS INC (TRDA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENTRADA THERAPEUTICS INC (TRDA) Sales and EPS estimates to see what analysts future expectations are.
- ENTRADA THERAPEUTICS INC (TRDA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENTRADA THERAPEUTICS INC (TRDA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENTRADA THERAPEUTICS INC (TRDA) Stock Chart to make your own analysis
- ENTRADA THERAPEUTICS INC (TRDA) Latest news and press-releases to stay up to date.
Does ENTRADA THERAPEUTICS INC (TRDA) stock pay dividends?
TRDA does not pay a dividend.
When does ENTRADA THERAPEUTICS INC (TRDA) report earnings?
ENTRADA THERAPEUTICS INC (TRDA) will report earnings on 2025-05-08, before the market open.
What is the Price/Earnings (PE) ratio of ENTRADA THERAPEUTICS INC (TRDA)?
The PE ratio for ENTRADA THERAPEUTICS INC (TRDA) is 4.76. This is based on the reported non-GAAP earnings per share of 1.91 and the current share price of 9.09 USD. Check the full fundamental report for a full analysis of the valuation metrics for TRDA.
What is the Short Interest ratio of ENTRADA THERAPEUTICS INC (TRDA) stock?
The outstanding short interest for ENTRADA THERAPEUTICS INC (TRDA) is 3.63% of its float. Check the ownership tab for more information on the TRDA short interest.
TRDA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TRDA. When comparing the yearly performance of all stocks, TRDA is a bad performer in the overall market: 86.73% of all stocks are doing better.
TRDA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TRDA. TRDA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
TRDA Financial Highlights
Over the last trailing twelve months TRDA reported a non-GAAP Earnings per Share(EPS) of 1.91. The EPS increased by 834.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.13% | ||
| ROA | 12.47% | ||
| ROE | 15.31% | ||
| Debt/Equity | 0 |
TRDA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to TRDA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -282% and a revenue growth -80.33% for TRDA